Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class A 002399

SZSE · China · Health Technology

CNY 9.85+0.24 (+2.50%)

Market closed· Sep 30, 2026, 7:04 AM UTC· CNY · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class A 002399

SZSE · China · Health Technology

CNY 9.85+0.24 (+2.50%)

Market closed· Sep 30, 2026, 7:04 AM UTC· CNY · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-12.44% · 6MFull-screen chart

Open CNY 9.61High CNY 9.92Low CNY 9.56Close CNY 9.85Volume 4.15M

Sep 30, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: CNY 9.61
Day range: CNY 9.56 – CNY 9.92
52-week range: CNY 8.50 – CNY 12.68
Volume: 4.15M
Market cap: CNY 13.06B
P/E (TTM): 71.2
Dividend yield (annualized): 1.47%
Next earnings date: 2026-11-04
Avg. volume (1Y): 4.69M

Performance

1 week

+1.23%

1 month

-1.89%

3 months

+4.79%

6 months

-11.73%

Year to date

-17.27%

1 year

-16.30%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: China
Exchange: SZSE
Shares outstanding: 1.25B
Employees: 2,150
ISIN: CNE100000P02
Beta: 1.19

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceMay 11, 2026

Resverlogix Announces One-Year Extension of Debenture

Calgary, Alberta--(Newsfile Corp. - May 11, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a one-year extension of the Company's US$6.0 million secured debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") (and payment of accrued interest thereon), extending the maturity date to May 13, 2027. In connection with the extension, the interest rate has been amended from 18% to 20% per annum, commencing on May 14, 2026."We appreciate...

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.